Maze Therapeutics (MAZE) EBITDA Margin (2024 - 2026)

Maze Therapeutics' (MAZE) quarterly EBITDA Margin came in at 132.76% in Q1 2026, down 366.06% quarter-over-quarter from 49.9% in Q4 2024.

Maze Therapeutics (MAZE) EBITDA Margin (2024 - 2026) Analysis & Trends

Maze Therapeutics has disclosed EBITDA Margin across 2 years of filings, most recently posting 132.76% for Q1 2026.

EBITDA Margin for Q1 2026 came in at 132.76%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 670.26% (changed N/A YoY), and the FY2024 annual result was 74.77%, changed N/A from the prior year.
EBITDA Margin came in at 132.76% for Q1 2026 at Maze Therapeutics, down from 49.9% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 93.04% in Q2 2024 to a low of 969.16% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-6.43%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	38.10%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Maze Therapeutics	1.31 Bn	1.31 Bn	18.21 Mn	-132.77%

Download Data